Intravenous administration of epoetin in haemodialysis patients.
Recombinant human erythropoietin (epoetin, rHuEPO) can be administered to haemodialysis patients intravenously or subcutaneously. Although the intravenous route is the originally approved and used route of administration, subcutaneous administration has been quite common throughout Europe since the introduction of prefilled syringes. The intravenous route has been shown to be as effective as the subcutaneous route, but patients should have adequate iron stores. In addition, intravenous administration is patient-friendly and results in fewer injections, less pain and bruising, and a minimised risk of immunogenicity. Furthermore, intravenous administration of epoetin is convenient for the nurse and is commonly used in Germany, Belgium and the USA. The purpose of this paper is to illustrate the very easy, practical ways of administering epoetin in prefilled syringes during dialysis at machine level, based on the authors' experiences in Belgium and Germany.
De Vos
Jean-Yves
JY
Dialysis Unit, AZ Werken Glorieux, Ronse, Belgium. devosjy@skynet.be
Upsing
Louise
L
D000740:Anemia / Q000097:blood / Q000209:etiology / Q000628:therapy; D001530:Belgium; D004356:Drug Storage; D004921:Erythropoietin / Q000008:administration & dosage*; D005858:Germany; D006801:Humans; D007275:Injections, Intravenous / Q000379:methods*; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000379:methods
D011994:Recombinant Proteins; D004921:Erythropoietin